Trial Profile

A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of P134 Cells in the Treatment of Recurrent Glioblastoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous chimeric antigen receptor T cell therapy Tasly Pharmaceutical Group (Primary) ; Autologous chimeric antigen receptor T cell therapy Tasly Pharmaceutical Group (Primary)
Indications Glioblastoma
Focus Adverse reactions
Sponsors Tasly Pharmaceutical Group

Most Recent Events

18 Feb 2026 The protocol has been amended to addition in safety endpoint.
18 Feb 2026 Planned number of patients changed from 24 to 26.
18 Feb 2026 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com